136 related articles for article (PubMed ID: 17985395)
21. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA).
Bendifallah N; Rasmussen FW; Zachar V; Ebbesen P; Nielsen PE; Koppelhus U
Bioconjug Chem; 2006; 17(3):750-8. PubMed ID: 16704214
[TBL] [Abstract][Full Text] [Related]
22. Intracellular delivery of siRNA by cell-penetrating peptides modified with cationic oligopeptides.
Ishihara T; Goto M; Kodera K; Kanazawa H; Murakami Y; Mizushima Y; Higaki M
Drug Deliv; 2009 Apr; 16(3):153-9. PubMed ID: 19514975
[TBL] [Abstract][Full Text] [Related]
23. Cell-penetrating peptides: Nanocarrier for macromolecule delivery in living cells.
Chugh A; Eudes F; Shim YS
IUBMB Life; 2010 Mar; 62(3):183-93. PubMed ID: 20101631
[TBL] [Abstract][Full Text] [Related]
24. Cell-Penetrating Peptides Selectively Cross the Blood-Brain Barrier In Vivo.
Stalmans S; Bracke N; Wynendaele E; Gevaert B; Peremans K; Burvenich C; Polis I; De Spiegeleer B
PLoS One; 2015; 10(10):e0139652. PubMed ID: 26465925
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of TAT cell membrane penetration efficiency by dimethyl sulphoxide.
Wang H; Zhong CY; Wu JF; Huang YB; Liu CB
J Control Release; 2010 Apr; 143(1):64-70. PubMed ID: 20025914
[TBL] [Abstract][Full Text] [Related]
26. Wasp mastoparans follow the same mechanism as the cell-penetrating peptide transportan 10.
Yandek LE; Pokorny A; Almeida PF
Biochemistry; 2009 Aug; 48(30):7342-51. PubMed ID: 19594111
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of cell-penetrating peptide-mediated peptide delivery.
Jones SW; Christison R; Bundell K; Voyce CJ; Brockbank SM; Newham P; Lindsay MA
Br J Pharmacol; 2005 Aug; 145(8):1093-102. PubMed ID: 15937518
[TBL] [Abstract][Full Text] [Related]
28. Distinct uptake routes of cell-penetrating peptide conjugates.
Lundin P; Johansson H; Guterstam P; Holm T; Hansen M; Langel U; EL Andaloussi S
Bioconjug Chem; 2008 Dec; 19(12):2535-42. PubMed ID: 19012426
[TBL] [Abstract][Full Text] [Related]
29. Penetration without cells: membrane translocation of cell-penetrating peptides in the model giant plasma membrane vesicles.
Säälik P; Niinep A; Pae J; Hansen M; Lubenets D; Langel Ü; Pooga M
J Control Release; 2011 Jul; 153(2):117-25. PubMed ID: 21420454
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationship study of the cell-penetrating peptide pVEC.
Elmquist A; Hansen M; Langel U
Biochim Biophys Acta; 2006 Jun; 1758(6):721-9. PubMed ID: 16808894
[TBL] [Abstract][Full Text] [Related]
31. Dynamics of transportan in bicelles is surface charge dependent.
Bárány-Wallje E; Andersson A; Gräslund A; Mäler L
J Biomol NMR; 2006 Jun; 35(2):137-47. PubMed ID: 16705358
[TBL] [Abstract][Full Text] [Related]
32. Effect of a Flexible Linker on Recombinant Expression of Cell-Penetrating Peptide Fusion Proteins and Their Translocation into Fungal Cells.
Gong Z; Walls MT; Karley AN; Karlsson AJ
Mol Biotechnol; 2016 Dec; 58(12):838-849. PubMed ID: 27734193
[TBL] [Abstract][Full Text] [Related]
33. Label-Free Confocal Raman Mapping of Transportan in Melanoma Cells.
Cosme PJ; Ye J; Sears S; Wojcikiewicz EP; Terentis AC
Mol Pharm; 2018 Mar; 15(3):851-860. PubMed ID: 29397737
[TBL] [Abstract][Full Text] [Related]
34. pVEC hydrophobic N-terminus is critical for antibacterial activity.
Alaybeyoglu B; Sariyar Akbulut B; Ozkirimli E
J Pept Sci; 2018 Jun; 24(6):e3083. PubMed ID: 29737576
[TBL] [Abstract][Full Text] [Related]
35. Visualization of the endocytic pathway in the filamentous fungus Aspergillus oryzae using an EGFP-fused plasma membrane protein.
Higuchi Y; Nakahama T; Shoji JY; Arioka M; Kitamoto K
Biochem Biophys Res Commun; 2006 Feb; 340(3):784-91. PubMed ID: 16380079
[TBL] [Abstract][Full Text] [Related]
36. In vitro uptake and stability study of pVEC and its all-D analog.
Elmquist A; Langel U
Biol Chem; 2003 Mar; 384(3):387-93. PubMed ID: 12715889
[TBL] [Abstract][Full Text] [Related]
37. Cell penetrating peptides fail to induce an innate immune response in epithelial cells in vitro: implications for continued therapeutic use.
Carter E; Lau CY; Tosh D; Ward SG; Mrsny RJ
Eur J Pharm Biopharm; 2013 Sep; 85(1):12-9. PubMed ID: 23958314
[TBL] [Abstract][Full Text] [Related]
38. Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay.
Mäger I; Eiríksdóttir E; Langel K; El Andaloussi S; Langel U
Biochim Biophys Acta; 2010 Mar; 1798(3):338-43. PubMed ID: 19909725
[TBL] [Abstract][Full Text] [Related]
39. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides.
Nekhotiaeva N; Elmquist A; Rajarao GK; Hällbrink M; Langel U; Good L
FASEB J; 2004 Feb; 18(2):394-6. PubMed ID: 14656995
[TBL] [Abstract][Full Text] [Related]
40. Cellular internalization kinetics of (luciferin-)cell-penetrating peptide conjugates.
Eiríksdóttir E; Mäger I; Lehto T; El Andaloussi S; Langel U
Bioconjug Chem; 2010 Sep; 21(9):1662-72. PubMed ID: 20684543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
